VivoSight detects 48% more basal cell carcinomas (BCCs) compared to clinical observation 

DOTmed issues an article on results from the US BCC study

Clinical trials in the U.S. have now shown that multi-beam Optical Coherence Tomography (‘OCT’) technology, may make diagnosis cut-free and immediate, according to English medical device company Michelson Diagnostics. In a multi-center study, its VivoSight OCT scanner, has been shown to significantly improve diagnosis of basal-cell carcinoma at an earlier stage and cut biopsies by 36 percent. The paper about this study appeared in the Journal of Clinical and Aesthetic Dermatology.

Click here to read more on this news article